Brought to you by 
Response Genetics grosses $3.9mm through PIPE
08 Apr 2010
Executive Summary
Response Genetics Inc. (PCR-based genetic tests for cancer) grossed $3.9mm through the sale of 3mm common shares at $1.31 each (a 7% premium) to Greenway Capital and associated funds (lead), Lansdowne Partners, and Paragon Associates.
Deal Industry
- In Vitro Diagnostics
- Laboratory Testing Services
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Bioinformatics
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Response Genetics grosses $3.9mm through PIPE
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice